TCR2 Therapeutics Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- TCR2 Therapeutics Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) for treating patients with solid tumors and hematological malignancies. The company's proprietary TRuC-T platform harnesses the full TCR signaling complex to specifically recognize and kill cancer cells independently of human leukocyte antigens; its lead product candidate, gavocabtagene autoleucel (gavo-cel), targets mesothelin-expressing tumors including non-small cell lung cancer, ovarian cancer, malignant pleural mesothelioma, peritoneal mesothelioma, and cholangiocarcinoma, and is in Phase 1/2 clinical trials. Additional pipeline candidates include TC-510, a mesothelin- and PD-L1-targeted TRuC-T cell in Phase 1/2 for solid tumors such as pancreatic adenocarcinoma; TC-520 for CD70-expressing renal cell carcinoma and acute myeloid leukemia; TC-310 targeting CD19 and CD22 for diffuse large B-cell lymphoma; and TC-410 for mesothelin and MUC16 in ovarian cancer, all at preclinical stages. Founded in 2015 and headquartered at 100 Binney Street in Cambridge, Massachusetts, TCR2 Therapeutics operates primarily in the United States with a focus on immuno-oncology, targeting oncologists, hematologists, and patients with advanced cancers through clinical trials and manufacturing facilities optimized for cGMP production. In June 2023, TCR2 Therapeutics completed an all-stock merger with Adaptimmune Therapeutics plc, under which Adaptimmune acquired TCR2, with Adaptimmune shareholders owning approximately 75% of the combined entity that continues as a leader in engineered T-cell therapies for solid tumors; the transaction integrated complementary platforms targeting mesothelin and MAGE-A4, extended cash runway into 2026, and added TCR2 board members to the combined board while ceasing independent TCRR trading on Nasdaq.
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
TCR² Therapeutics: Betting On A Solid Reversal
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks
TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference
TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference
TCRR Stock: Why It Increased Today
TCR² Therapeutics to Host R&D Day on October 20, 2021
TCRR Stock: Why It Significantly Decreased Today
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors
TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference